<DOC>
	<DOC>NCT02189837</DOC>
	<brief_summary>This is a randomized, double-blind, placebo-controlled trial to evaluate the effect of evolocumab, atorvastatin, and combination therapy on lipoprotein kinetics.</brief_summary>
	<brief_title>Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Fasting LDLC at screening ≥ 100 mg/dL and ≤ 190 mg/dL Fasting triglycerides ≤ 150 mg/dL Body mass index (BMI) between 18.0 and 32.0 kg/m^2 Framingham cardiac risk score 10% or less Treatment with a lipidregulating drug or over the counter supplement in the last 3 months prior to screening History of coronary heart disease (CHD) or CHD equivalent Uncontrolled hypertension Diabetes mellitus</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Raised cholesterol</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>Elevated Cholesterol</keyword>
	<keyword>Hyperlipidemias</keyword>
	<keyword>Dyslipidemias</keyword>
	<keyword>Lipid Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
</DOC>